Lupin Gets USFDA Nod To Market Its Skin Cream

New Delhi: Drug major Lupin has received final approval from the US health regulator to market its Desoximetasone cream, used for treatment of skin disease, in the American market. Lupin said in a BSE filing that it "has received final approval for its Desoximetasone cream USP, 0.05 per cent and Desoximetasone cream USP, 0.25 per cent from the United States Food and Drug Administration (USFDA)". The products to be marketed are gene...